Abbott Laboratories: FreeStyle Libre CGMs And EPD Business Driving Positive Momentum

Abbott Laboratories is poised for sustained growth, primarily driven by its FreeStyle Libre CGM segment, which anticipates a 15% CAGR by 2028 through enhanced global accessibility, and its Established Pharmaceutical Products (EPD) business, bolstered by new biosimilar acquisitions and double-digit CAGR in emerging markets, potentially leading to EPS growth beyond medical devices. This strategic momentum, coupled with a strong balance sheet and over 50 consecutive years of dividend increases, positions Abbott as a robust long-term investment.

Analysis

Abbott Laboratories is positioned for sustained growth, underpinned by strong performance in two key divisions. The FreeStyle Libre Continuous Glucose Monitoring (CGM) business is projected to achieve a 15% compound annual growth rate (CAGR) in sales by 2028, driven by strategic collaborations enhancing global patient access. Simultaneously, the Established Pharmaceutical Products (EPD) segment is set to stimulate earnings growth beyond Medical Devices, bolstered by the acquisition of rights to four new biosimilar products and exposure to emerging markets with double-digit CAGR potential. This dual-engine growth strategy is supported by an excellent balance sheet and a formidable track record of capital returns, highlighted by over 50 consecutive years of dividend increases, reinforcing its status as a robust long-term investment.

Key Decisions for Investors

• Investors should evaluate Abbott's long-term growth potential, which is significantly enhanced by the projected 15% CAGR in its FreeStyle Libre franchise and the expansion of its EPD business into high-growth emerging markets.
• For income-oriented portfolios, Abbott's consistent history of over 50 consecutive years of dividend increases, supported by a strong balance sheet, presents a compelling case for consideration as a core holding.
• It is prudent to monitor quarterly sales figures for the FreeStyle Libre platform and track the execution of the biosimilar strategy in emerging markets to validate the company's projected earnings growth.